{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:27:19Z","timestamp":1761182839449,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/s10156-011-0249-7","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T07:11:07Z","timestamp":1303974667000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C"],"prefix":"10.1016","volume":"17","author":[{"given":"Hiroaki","family":"Ikezaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Taniai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosaburo","family":"Kainuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-011-0249-7_bib0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.510250334","article-title":"Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection","volume":"25","author":"Hayashi","year":"1997","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1007\/s10156-011-0249-7_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1590-8658(00)80831-2","article-title":"Intracellular signaling and antiviral effects of interferons","volume":"32","author":"Heim","year":"2000","journal-title":"Dig Liver Dis"},{"key":"10.1007\/s10156-011-0249-7_bib0020","series-title":"Hepatitis C virus disease: immunobiology and clinical applications","article-title":"Interferon-induced effector proteins and hepatitis C virus replication","author":"Frese","year":"2008"},{"key":"10.1007\/s10156-011-0249-7_bib0025","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C. A systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0030","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1007\/s10156-011-0249-7_bib0035","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomized trial of interferon alpha2b plus ribavirin for 48\u00a0weeks or for 24\u00a0weeks versus interferon alpha2b plus placebo for 48\u00a0weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1007\/s10156-011-0249-7_bib0040","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3748\/wjg.v12.i5.784","article-title":"Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group","volume":"12","author":"Furusyo","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1007\/s10156-011-0249-7_bib0045","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1440-1746.2008.05319.x","volume":"23","author":"Furusyo","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1007\/s10156-011-0249-7_bib0050","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.3748\/wjg.v16.i35.4400","article-title":"Pegylated interferon \u03b1-2b plus ribavirin for older patients with chronic hepatitis C","volume":"16","author":"Kainuma","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1007\/s10156-011-0249-7_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/00365520600955526","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) and ribavirin","volume":"42","author":"Foster","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1007\/s10156-011-0249-7_bib0060","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24\u00a0weeks peginterferon alpha-2a (40\u00a0kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1007\/s10156-011-0249-7_bib0070","first-page":"S3","article-title":"National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1007\/s10156-011-0249-7_bib0080","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1007\/s10156-011-0249-7_bib0085","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1128\/JCM.00163-06","article-title":"Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection","volume":"44","author":"Halfon","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0090","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1128\/JCM.00058-07","article-title":"Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus","volume":"45","author":"Sabato","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0095","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/JCM.02385-06","article-title":"Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA","volume":"45","author":"Schutten","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0100","first-page":"96","article-title":"Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA","volume":"38","author":"Michelin","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0105","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1128\/JCM.38.6.2210-2214.2000","article-title":"Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination","volume":"38","author":"Gerken","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0110","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JCM.40.3.768-773.2002","article-title":"Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay","volume":"40","author":"Konnick","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jviromet.2003.10.001","article-title":"Performance attributes of LCx HCV RNA quantitative assay","volume":"115","author":"Leckie","year":"2004","journal-title":"J Virol Methods"},{"key":"10.1007\/s10156-011-0249-7_bib0120","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1128\/JCM.38.11.4171-4179.2000","article-title":"Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics","volume":"38","author":"Lee","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0125","first-page":"2151","article-title":"A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C","volume":"89","author":"Hayashi","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1007\/s10156-011-0249-7_bib0130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0135","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1128\/JCM.02329-08","article-title":"Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay","volume":"47","author":"Pyne","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/JCM.01753-08","article-title":"Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep\/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients","volume":"47","author":"Matsuura","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1007\/s10156-011-0249-7_bib0145","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jcv.2007.05.007","article-title":"Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay","volume":"39","author":"Fytili","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1007\/s10156-011-0249-7_bib0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jcla.1042","article-title":"Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA","volume":"15","author":"Ross","year":"2001","journal-title":"J Clin Lab Anal"},{"key":"10.1007\/s10156-011-0249-7_bib0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2005.08.016","article-title":"Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse","volume":"44","author":"Gerotto","year":"2006","journal-title":"J Hepatol"},{"key":"10.1007\/s10156-011-0249-7_bib0160","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/gast.2002.33428","article-title":"Molecular diagnosis of viral hepatitis","volume":"122","author":"Pawlotsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1007\/s10156-011-0249-7_bib0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.1007\/s10156-011-0249-7_bib0170","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7883\/yoken.63.307","article-title":"A hepatitis C virus\u2013host interaction involved in viral replicon: toward the identification of antiviral targets","volume":"63","author":"Suzuki","year":"2010","journal-title":"Jpn J Infect Dis"},{"key":"10.1007\/s10156-011-0249-7_bib0175","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":"Antiviral action of ribavirin in chronic hepatitis C","volume":"126","author":"Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1007\/s10156-011-0249-7_bib0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy on interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1007\/s10156-011-0249-7_bib0185","first-page":"1134A","article-title":"Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (PEG) plus ribavirin (RBV): results of the IDEAL trial","volume":"48","author":"Sulkowski","year":"2008","journal-title":"Hepatology"},{"key":"10.1007\/s10156-011-0249-7_bib0190","unstructured":"Nyberg LM, Shiffman ML, Bonilla H, Hu KQ, Morgan TR, Levine RA, et al. Predicting the ability to achieve a sustained virologic response (SVR) in the first 12\u00a0weeks: results from the IDEAL study. Hepatology. 2008;48:1134A (abstract)."}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X11704044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X11704044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-011-0249-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:47:03Z","timestamp":1761158823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X11704044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"alternative-id":["S1341321X11704044"],"URL":"https:\/\/doi.org\/10.1007\/s10156-011-0249-7","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-011-0249-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}